A neurologist at St Vincent's Hospital shared recently presented findings from a phase 2 study of tazbentetol, a novel synaptogenic small molecule, in mild-to-moderate Alzheimer disease. [WATCH TIME: 4 minutes]
Bruce Brew, MD, DSc, FRACP, FAAN
Advertisement
Director of the Peter Duncan Neurosciences Unit at St Vincent's Hospital in Sydney, Australia.
Articles by Bruce Brew, MD, DSc, FRACP, FAAN
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
A Clinical Review of the 2025 Neuromyelitis Optica Spectrum Disorder Guidelines
2
FDA Action Update, December 2025: Acceptance, Approval, and Clearance
3
FDA Approves Generic Glatiramer Acetate Injection for Multiple Sclerosis Treatment
4
Assessing Phase 2 Data of Tazbentetol in Alzheimer Disease: Bruce Brew, MD, DSc, FRACP, FAAN
5